In conclusion, by introducing transcriptome network analysis into the discovery of NSCLC therapeutic target, we successfully identified PSMD2, which was significantly correlated with the poor prognosis of NSCLC patients and could serve as a novel therapeutic target. Here, PSMD2 is linked to non-small cell lung carcinoma.